oasis 1 oral semaglutide 50 mg obesity nejm 2023 results in Adults with Type Diabetes and 50 mg of oral #semaglutide

More substantial changes can be expected after approximately four weeks

Semaglutide may begin new era for pediatric obesity treatment Claudia Fox During a panel discussion following the presentation, experts stated that semaglutide could change the landscape of pediatric obesity treatment

Its important to acknowledge that semaglutide is extensively used in managing type 2 diabetes and obesity, with potential benefits in weight loss and cardiovascular risk reduction

Side effects include reflux, nausea, vomiting, abdominal cramping, constipation, diarrhea, wrinkles, and sagging skin on your face

The multidisciplinary team of GI providers, gut-brain specialists, and registered dietitians at Oshi Health can offer a tailored treatment plan to help you implement the lifestyle and behavioral adjustments needed to reduce GI side effects associated with GLP-1 drugs